The IRF2 (Interferon Regulatory Factor 2) antibody is a crucial tool for studying the role of IRF2. a transcription factor belonging to the IRF family, which regulates interferon (IFN)-mediated immune responses and cellular processes. IRF2 typically acts as a transcriptional repressor, counterbalancing IRF1’s activity by binding to similar IFN-stimulated response elements (ISREs) in gene promoters. It plays roles in immune regulation, cell cycle control, apoptosis, and oncogenesis. Structurally, IRF2 contains a conserved N-terminal DNA-binding domain and a C-terminal repression domain. Antibodies targeting IRF2 are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to detect its expression, localization, and DNA-binding activity in various tissues or cell lines. Research involving IRF2 antibodies has highlighted its dual role in cancer—acting as a tumor suppressor in some contexts (e.g., by repressing oncogenic genes) or as an oncogene in others (e.g., promoting immune evasion). These antibodies also help investigate IRF2’s interplay with signaling pathways like STAT or NF-κB. Specific clones (e.g., clone D9G1) are validated for specificity using knockout controls, ensuring reliable detection of the ~48 kDa protein. Studies using IRF2 antibodies have advanced understanding of viral immunity, autoimmune diseases, and cancer immunotherapy strategies.